Company Snapshot: Equillium, Inc.

EQ
Last	Change	Volume	High	Low

Company Overview

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Client News

1. Apr 3 2024 Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2. Apr 1 2024 Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
3. Mar 25 2024 Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4. Mar 22 2024 Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
5. Dec 21 2023 Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease